Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,614 Mln
Revenue (TTM)
$14 Mln
Net Profit (TTM)
$0 Mln
ROE
-2 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
32.5
Industry P/E
28.25
EV/EBITDA
-9.4
Div. Yield
0 %
Debt to Equity
2.1
Book Value
$--
EPS
$--
Face value
--
Shares outstanding
85,484,496
CFO
$-276.68 Mln
EBITDA
$-323.08 Mln
Net Profit
$-348.75 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Liquidia Technologies Inc (LQDA)
| 41.7 | 21.4 | 1.0 | 24.8 | 42.2 | 12.4 | -- |
|
BSE Sensex*
| 3.9 | 2.4 | 8.0 | 10.0 | 14.4 | 21.3 | 11.3 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|
|
Liquidia Technologies Inc (LQDA)
| -2.2 | 88.9 | 30.8 | 65.1 | -31.0 | -80.3 |
|
S&P Small-Cap 600
| 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Liquidia Technologies Inc (LQDA)
|
16.7 | 1,614.0 | 14.1 | -127.8 | -815.8 | -159.6 | -- | 32.5 |
| 20.1 | 4,879.7 | 459.4 | 206.8 | 25.6 | 68.3 | 24.3 | 12.9 | |
| 105.8 | 5,334.8 | 432.2 | -278.3 | -64.1 | -380.9 | -- | 100.3 | |
| 58.5 | 11,493.1 | 2,937.8 | 523.9 | 23.2 | 9.3 | 22.2 | 2.0 | |
| 32.8 | 6,400.9 | 127.4 | -668.0 | -432.9 | -- | -- | 123.7 | |
| 75.8 | 8,082.8 | 685.5 | 132.9 | 15.6 | 20.1 | 66.3 | 11.6 | |
| 12.6 | 6,496.1 | 4,427.0 | 373.0 | -0.7 | 5.8 | 17.4 | 1.0 | |
| 64.8 | 12,640.1 | 4,413.2 | 21.3 | 7.2 | 0.6 | 326.5 | 3.4 | |
| 84.4 | 4,326.8 | 1,137.8 | 214.6 | 29.2 | 12.3 | 20.4 | 2.4 | |
| 8.5 | 10,422.3 | 14,317.0 | -3,790.1 | -23.7 | -21.4 | -- | 0.7 |
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of... treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina. Read more
CEO & Director
Dr. Roger A. Jeffs Ph.D.
CEO & Director
Dr. Roger A. Jeffs Ph.D.
Headquarters
Morrisville, NC
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Liquidia Technologies Inc (LQDA) stood at $ 288 Mln as on 31-Mar-25
The share price of Liquidia Technologies Inc (LQDA) is $16.66 (NASDAQ) as of 21-May-2025 16:00 EDT. Liquidia Technologies Inc (LQDA) has given a return of 42.23% in the last 3 years.
Liquidia Technologies Inc (LQDA) has a market capitalisation of $ 1,614 Mln as on 16-May-2025. As per Value Research classification, it is a Small Cap company.
The P/B ratio of Liquidia Technologies Inc (LQDA) is 32.47 times as on 16-May-2025, a 597% premium to its peers’ median range of 4.66 times.
Since, TTM earnings of Liquidia Technologies Inc (LQDA) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Liquidia Technologies Inc (LQDA) and enter the required number of quantities and click on buy to purchase the shares of Liquidia Technologies Inc (LQDA).
Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company also offers Remodulin, a treprostinil administered through continuous intravenous and subcutaneous infusion; and develops L606, an investigational liposomal formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The company has a license agreement with Pharmosa Biopharm Inc to develop and commercialize L606, an inhaled sustained-release formulation of Treprostinil for the treatment of PAH and PH-ILD. Liquidia Corporation was founded in 2004 and is based in Morrisville, North Carolina.
The CEO & director of Dr. Roger A. Jeffs Ph.D.. is Liquidia Technologies Inc (LQDA), and CFO & Sr. VP is Dr. Roger A. Jeffs Ph.D..
There is no promoter pledging in Liquidia Technologies Inc (LQDA).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,178
|
|
|
1,126
|
|
|
988
|
|
|
751
|
|
|
647
|
|
|
639
|
|
|
510
|
|
|
475
|
|
|
422
|
| Liquidia Technologies Inc (LQDA) | Ratios |
|---|---|
|
Return on equity(%)
|
-159.56
|
|
Operating margin(%)
|
-815.75
|
|
Net Margin(%)
|
-903.8
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Liquidia Technologies Inc (LQDA) was $0 Mln.
$-0.36
(
